| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Xenon Pharmaceuticals Inc. (XENE) has 5 insiders with recent SEC Form 4 filings, including 4 buys and 7 sells. XENE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 30.0K | $1.64M | - | |
| Other | 20.0K | $1.10M | - | |
| CEO | 19.9K | $1.09M | - | |
| Other | 7.3K | $400.0K | - | |
| Other | 7.1K | $387.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2016 | Holler Frank A | Director | Sell | 11,938 | $7.65 | $91,337.64 | -7.6% | |
| Aug 18, 2016 | Holler Frank A | Director | Sell | 18,062 | $7.93 | $143,156.05 | -3.5% | |
| Jun 24, 2016 | Mortimer Ian57 | CFO &COO | Buy | 5,300 | $6.22 | $32,940.00 | +132.5% | |
| Sep 24, 2015 | Goldberg Y. Paul | VP Of Clinical Development | Sale+OE | 22,149 | $8.88 | $196,664.31 | -32.5% |